← Leaderboards
Manish S Patankar
Wm S. Middleton Memorial Veterans Hosp
$3,121,908
Attributed
$4,734,751
Total exposure
9
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2009–25$2M$1.5M$1M$500K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,734,751 · 8
VA$0 · 1
By mechanism
R01$2,083,329 · 1
S10$950,678 · 2
P30$760,525 · 2
R21$749,628 · 2
R41$190,591 · 1
I01$0 · 1
Top collaborators
- Paul J. Campagnola6 shared
- Kevin William Eliceiri6 shared
- Joseph P Connor2 shared
- Rachel Hannah Kravitz1 shared
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsExperimental StudyMalignant NeoplasmsMonitorBaseMalignant Neoplasm Of OvaryInstrumentData AnalysesBiometryFlow CytometryReproducibilityCancer TherapyBiologicalTechnologyDiagnosisTumorWisconsinFutureGenerationsDesignOvarian NeoplasmEtiologyProgramsLaboratories
Grant awards (28)
Flow Cytometry Laboratory$39,393
P30 · FY2025 · CA · contact PI
Using a chemical biology approach to develop novel inhibitors of mitochondrial oxidative phosphorylation for the treatment of ovarian cancer$0
I01 · FY2025 · VA · contact PI
Flow Cytometry Laboratory$39,393
P30 · FY2024 · CA · contact PI
Using a chemical biology approach to develop novel inhibitors of mitochondrial oxidative phosphorylation for the treatment of ovarian cancer$0
I01 · FY2024 · VA · contact PI
Flow Cytometry Laboratory$39,393
P30 · FY2023 · CA · contact PI
Using a chemical biology approach to develop novel inhibitors of mitochondrial oxidative phosphorylation for the treatment of ovarian cancer$0
I01 · FY2023 · VA · contact PI
Flow Cytometry Laboratory Shared Resource$110,216
P30 · FY2022 · CA · contact PI
Using a chemical biology approach to develop novel inhibitors of mitochondrial oxidative phosphorylation for the treatment of ovarian cancer$0
I01 · FY2022 · VA · contact PI
Flow Cytometry Laboratory Shared Resource$128,672
P30 · FY2021 · CA · contact PI
Quantitative assessment of the role of collagen alterations in ovarian cancer$447,811
R01 · FY2020 · CA
Developing non-human primate models for ovarian cancer$399,185
R21 · FY2020 · CA · contact PI
Flow Cytometry Laboratory Shared Resource$128,747
P30 · FY2020 · CA · contact PI
Quantitative assessment of the role of collagen alterations in ovarian cancer$377,861
R01 · FY2019 · CA
Flow Cytometry Laboratory Shared Resource$128,750
P30 · FY2019 · CA · contact PI
Quantitative assessment of the role of collagen alterations in ovarian cancer$61,961
R01 · FY2019 · CA
BD FACSymphony High Parameter Flow Cytometer$600,173
S10 · FY2018 · OD · contact PI
Quantitative assessment of the role of collagen alterations in ovarian cancer$389,549
R01 · FY2018 · CA
Flow Cytometry Laboratory Shared Resource$125,007
P30 · FY2018 · CA · contact PI
Flow Cytometry Laboratory Shared Resource$10,871
P30 · FY2018 · CA · contact PI
Flow Cytometry Laboratory Shared Resource$5,924
P30 · FY2018 · CA · contact PI
Flow Cytometry Laboratory Shared Resource$3,293
P30 · FY2018 · CA · contact PI
Flow Cytometry Laboratory Shared Resource$866
P30 · FY2018 · CA · contact PI
Quantitative assessment of the role of collagen alterations in ovarian cancer$418,598
R01 · FY2017 · CA
Quantitative assessment of the role of collagen alterations in ovarian cancer$387,549
R01 · FY2016 · CA
Special BD LSR Fortessa$350,505
S10 · FY2014 · OD · contact PI
Ovarian cancer diagnosis by monitoring immune cell bound MUC16 (CA125)$156,650
R21 · FY2011 · CA · contact PI
Ovarian cancer diagnosis by monitoring immune cell bound MUC16 (CA125)$193,793
R21 · FY2010 · CA · contact PI
Improving Ovarian Cancer Treatment by Targeting a Novel Epitope of MUC16$190,591
R41 · FY2009 · CA